Skip to content
OpenCapital
Get started

MaxCyte MXCT License — Revenue

Other product segments

Assay And Other Service Revenue
$482K+21.4%

Similar metrics at other companies

Dianthus Therapeutics logo
DNTHLicense — Revenue
$463K-60.2%
NetSol Technologies logo
NTWKLicense — Revenue
$4.73M+394,592%
electroCore, Inc. logo
ECORLicense — Revenue
$17K+13.3%
Ceva logo
CEVALicense — Revenue
$17.82M+18.5%
Eton Pharmaceuticals, Inc. logo
ETONLicense — Revenue
$0-100%
eGain logo
EGANLicense — Revenue
$20.92M+6.9%

Other financials

Income statement

See full
Revenue$9.7M-7.1%
Gross profit$8.1M-9.1%
Operating income-$6.2M+49.7%
Net income-$4.8M+53.7%
EPS (diluted)-$0.04+60.0%

Balance sheet

See full
Cash & equivalents$14.6M-37.8%
Total debt$17.5M-7.1%
Total equity$167.9M-15.8%
Total assets$194.5M-15.4%

Cash flow

See full
Operating cash flow-$8.2M+43.3%
CapEx$72.0K-89.0%
Free cash flow-$8.2M+45.3%

Valuation

See full
Market cap$130.15M-46.8%
Enterprise value$133.08M-46.3%
P/S4×-2.8×

Profitability

See full
Gross margin80.5%-0.4pp
Operating margin-141.8%+6.4pp
Net margin-121.2%+12.3pp
FCF margin-90.9%+3.7pp

Returns & leverage

See full
Return on equity-21.3%+2.0pp
Debt / equity0.1×0.0×
Current ratio12×-0.2×

Where this comes from

Reported directly by MaxCyte in its filing.

Tagged under the XBRL concept us-gaap:Revenues.

The official record: MaxCyte’s 10-Q, filed May 13, 2026, on SEC EDGAR. View the filing →

Ask your AI about MaxCyte's license — revenue.

Connect your AI assistant and compare segments, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is MaxCyte's license — revenue?
MaxCyte (MXCT) reported license — revenue of $5.53M in Q1 2026.
How has MaxCyte's license — revenue changed year-over-year?
MaxCyte's license — revenue increased by 18.2% year-over-year, from $4.68M to $5.53M.
What does license — revenue mean?
This metric represents the total revenue recognized from contractual agreements with customers within the licensing segment, excluding any pass-through taxes. It captures the core income generated from granting rights to proprietary technology or intellectual property platforms. This figure serves as a primary indicator of the commercial adoption and market demand for the company's core technology offerings.